Editor: Deborah Sesok-Pizzini, MD, MBA, adjunct professor, Department of Clinical Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and vice chair for clinical pathology and transfusion medicine, Nemours Children’s Health, Wilmington, Del.
Alpha-gal immunoglobulin E seroprevalence among blood donors
November 2026—Alpha-gal syndrome (AGS) is a newly described emerging noninfectious tickborne disease characterized by an allergic reaction to galactose-a-1,3-galactose (alpha-gal), an oligosaccharide found in red (mammalian) meat and other animal products, such as gelatin and dairy. As of 2022, an estimated 450,000 people in the United States had developed AGS. In the most severe cases, the disease can cause death from anaphylactic reactions. Allergic reactions encompass a range of symptoms, including urticaria, angioedema, wheezing, and gastrointestinal distress. Allergic reactions are primarily managed through dietary avoidance. The geographic distribution of the disease is closely associated with the geographic distribution of the lone star tick (Amblyomma americanum). Bites from this tick introduce alpha-gal through saliva transfer, which can then trigger the allergy. AGS is diagnosed via IgE antibodies against alpha-gal and the appearance of clinical symptoms. The number of people in the United States who are seropositive for alpha-gal IgE is unknown. The authors conducted a study to glean a better understanding of the distribution and seroprevalence of alpha-gal IgE among U.S. adults. The study involved 3,000 serum samples collected from November 2024 to April 2025 from blood donors living in 10 states: Arkansas, Kentucky, Maine, Minnesota, Missouri, New Mexico, South Carolina, Tennessee, Virginia, and Washington. Three hundred samples were collected per state. Demographic variables, including age, sex, race, ethnicity, zip code, and county of residence, were also obtained from the blood donors. The American Red Cross and Vitalant got consent to use specimens for research purposes from blood donors at the time of blood donation, per routine protocol. An alpha-gal IgE titer of 0.1 kU/L or more was considered a positive result. The blood donors in the study were a median age of 62 years. A total of 56.2 percent of donors were male; 92.9 percent were white, and 93.4 were not Hispanic or Latino. The estimated alpha-gal IgE seroprevalence ranged from 1.1 percent in Washington to 31.2 percent in Arkansas. The estimated geometric mean alpha-gal IgE titers were highest in Kentucky and lowest in Washington. The combined estimated seroprevalence in the five states with the highest rates—Arkansas, Kentucky, Missouri, Tennessee, and Virginia—was 24 percent. The U.S. geographic distribution of alpha-gal IgE seroprevalence is similar to the distributed cases of AGS. The authors found that this estimate of state-level alpha-gal IgE seroprevalence exceeded the 2022 estimate of up to 450,000 people nationwide affected by AGS. They noted that as AGS becomes a reportable condition in an increasing number of states and disease-surveillance efforts increase, more data will be available to determine the percentage of seropositive people who are also allergic and at risk of developing AGS.
Saunders EF, Taylor ML, Jones ES, et al. Alpha-gal immunoglobulin E seroprevalence among blood donors—10 states, 2024-2025. MMWR. 2026;75(25): 315–321.
Correspondence: Dr. Johanna S. Salzer at hio7@cdc.gov
Intravenous iron to treat anemia before cardiac surgery
Perioperative anemia is not an uncommon risk factor for patients undergoing cardiac surgery and increases the need for RBC transfusion. Approximately 20 to 50 percent of patients undergoing cardiac surgery receive a blood transfusion. Because anemia and transfusion are associated with a greater number of complications, longer hospital stays, and increased mortality after cardiac surgery, it is important to reduce the incidence of anemia preoperatively. Iron deficiency is the most common cause of anemia. Yet intravenous iron is a readily available and cost-effective treatment for patients undergoing major surgery, including cardiac surgery. Intravenous iron was shown in a 2024 systematic review of clinical trials to reduce the need for RBC transfusions. However, these data did not show a beneficial effect on postoperative complications or other outcomes. The ITACS (Intravenous Iron to Treat Anaemia before Cardiac Surgery) trial examined whether intravenous iron supplementation in patients with preoperative anemia improves recovery and reduces complications, thereby reducing lengths of hospital stay. The authors evaluated the effects of intravenous iron on RBC transfusion and recovery after cardiac surgery in the international multicenter double-blind placebo-controlled randomized ITACS trial. They enrolled in the study—between July 2016 and December 2023—adults with anemia undergoing elective cardiac surgery at 33 hospitals in 10 countries. The authors used a computer-generated program to randomize participants to receive 1,000 mg of intravenous iron or a placebo one to 26 weeks before surgery. All participants, clinicians, and data collectors were blinded to the intervention. The primary outcome was the number of days alive and at home up to 90 days after surgery. Secondary outcomes were RBC transfusion requirements and complications. Of 2,993 screened patients, 955 were enrolled, 939 were included in the intention-to-treat population at baseline, and 921 of the intention-to-treat patients were assessed for the primary outcome. The median number of days alive and at home up to 90 after surgery was 81.1 (74.8–83.7) in patients assigned to the intravenous iron group and 80.0 (69.5–83.6) in those receiving placebo (adjusted median difference, 1.0 day; 95.4 percent confidence interval [CI], 0–2.1 days; P=.041). Red blood cell transfusions were given to 262 (61.1 percent) patients in the iron group and 302 (68.2 percent) in the placebo group during their hospital stay (relative risk, 0.90; 95 percent CI, 0.82–0.99; P=.027). No differences were observed in length of hospital stay or major complications. The authors showed that patients with anemia undergoing elective cardiac surgery who received intravenous iron had fewer RBC transfusions and a small improvement in days alive and at home during the first 90 days. They concluded that intravenous iron was an effective component of patient blood management and increased preoperative hemoglobin concentration and partially corrected anemia, which reduced RBC transfusions and led to an extra day at home in the first 90 days after surgery.
Myles PS, Klein AA, Smith JA, et al. Intravenous iron to treat anaemia before cardiac surgery (ITACS): international, double blind, placebo controlled randomised trial. BMJ. 2026. dx.doi.org/10.1136/bmj-2026-100407
Correspondence: Dr. P. S. Myles at p.myles@alfred.org.au